A record year for UK late-stage funding is real. So is the fact that most of the biggest cheques are coming from outside Britain and the pension money that was supposed to close that gap has moved a fraction of the promised distance.
In March, three high-profile names joined the board of Nscale, the London-based AI infrastructure company: Sheryl Sandberg, formerly of Meta; Susan Decker, formerly of Yahoo; and Nick Clegg, formerly of Meta and, before that, Britain's deputy prime minister.
The company had just closed a $2 billion Series C funding round at a $14.6 billion valuation, the largest of its kind ever raised in Europe.
Look at who actually led that round, though, and the picture gets more interesting, not Atomico, not Balderton and not any of the growth equity funds most people would name if you asked them who backs Britain's biggest scale-ups. The lead investors were Aker ASA, a Norwegian industrial group, and 8090 Industries, a New York firm best known for backing nuclear energy start-ups.
The rest of the round reads like a hedge fund roster: Citadel, Point72, Jane Street, alongside strategic money from Nvidia, Dell and Nokia.
Nscale is a British company, and almost none of the capital that just valued it at $14.6 billion is.
That's the story sitting underneath the UK's genuinely impressive 2026 funding numbers, and we really think it deserves more attention than it's getting right now.
The Numbers Are Real
UK startups raised $23.6 billion in venture capital in 2025, a 35% increase on 2024 and the first annual growth in four years. The momentum has continued into 2026: according to Dealroom and HSBC Innovation Banking, UK companies raised roughly $17 billion in the first half of the year alone, more than double the same period in 2025, and enough to put Britain ahead of the next three largest European markets combined.
Late-stage investment is doing almost all of the heavy lifting. In H1 2026, late-stage rounds accounted for 68% of all capital raised, up from just 42% a year earlier.
“UK AI startups raised $5.8 billion in the first quarter alone, equivalent to 74% of all venture capital invested. This is not simply a surge in interest, but a sign that AI is becoming foundational across sectors.”— Emily Turner, CEO, HSBC Innovation Banking UK
Growth equity funds, which was once the quietest corner of UK venture, are suddenly where all the money is concentrated. There were 36 megarounds of $100 million or more in 2025, many of them Series C funding rounds in their own right - PhysicsX's £225 million raise, Oxford Quantum Circuits' £260 million round.
Series A and B funds, meanwhile, are largely sitting on dry powder raised during the boom years, waiting to be deployed rather than driving this particular surge.
So Once Again Who's Writing the Cheques?
Traditional growth equity funds still exist and still matter.
Atomico's $754 million Growth VI fund backs founders from Series B through to pre-IPO funding rounds, Balderton runs a dedicated $685 million growth fund alongside its early-stage vehicle, Index, which closed $2.3 billion across venture and growth strategies in a single raise.
London-headquartered growth equity funds like Vitruvian Partners, writing cheques between roughly €40 million and €600 million, and Permira, sitting on some €80 billion in assets, remain active too.
These are the growth equity funds the “who's backing UK start-ups” conversation is usually built around, but now lets look at where the single biggest cheques are actually landing, and then a different picture takes over.
Wayve's $1.2 billion Series D in February, valuing the autonomous driving company at $8.6 billion, was led not by a growth equity fund at all but by SoftBank Vision Fund 2 alongside Eclipse and Balderton, with Nvidia, Microsoft, Uber, Mercedes-Benz, Nissan and Stellantis all writing cheques alongside them. PhysicsX's Series C was led by Temasek, Singapore's sovereign wealth fund. US crossover funds are moving in too: Thrive Capital led Isomorphic Labs' $2.1 billion Series B, one of the largest life sciences rounds in British history.
This is what happens when a company's technology matters strategically to industries that already have the money. Automakers, chipmakers and sovereign capital want a seat at the table, not just a return.
The Government Is Trying to Close the Gap Itself
The British Business Bank's direct equity portfolio has doubled more since October 2025, from £290 million to over £600 million, spread across more than 50 companies, so that means more capital deployed in whole nine months than in the previous four years combined.
Its new £200 million British Growth Partnership had its first close in March 2026, with Aegon UK, NatWest Cushon and M&G as backers.
British Patient Capital, the Bank's commercial subsidiary, has quietly become the most active growth-stage investor in UK life sciences, it sits alongside the National Wealth Fund's own growing appetite for equity stakes in scaling businesses, and a fresh £500 million Sovereign AI Fund that launched in April 2026 specifically to write £1 million to £10 million cheques directly into British AI companies.
British Patient Capital's mandate is explicitly the kind of long-term, patient capital that pension funds are uniquely suited to provide, and that domestic growth equity funds have historically struggled to raise at scale.
Now that's a genuine, coordinated push, and it still isn't close to matching what's arriving from overseas.
The Pension Money That Hasn't Turned Up
The most ambitious attempt to fix this domestically is the Mansion House Compact, under which eleven of Britain's largest pension funds committed, in 2023, to put 5% of their default pension funds into unlisted equity by 2030, it's a pledge meant to unlock roughly £50 billion for exactly this kind of growth equity funding gap.
Three years on, Mansion House Compact signatories hold £1.6 billion of unlisted equity across their default pension funds, that's 0.6% of assets, up from 0.36% the year before.
This is progress, but nowhere near the pace the 2030 target requires.
“It is clear the pace must increase significantly for Mansion House Compact signatories to meet their commitments.”— Michael Moore, Chief Executive, UK Private Capital
UK Private Capital, the trade body formerly known as the BVCA, surveyed 83 growth equity funds and venture firms this spring and found just two legally binding commitments had actually materialised from Mansion House Compact pension funds, with six more in active negotiation.
The same research found that British private capital received 16.5 times as much foreign investment as domestic investment in 2025 - a ratio that puts the pension shortfall in fairly stark context, and one that feeds directly into the phrase now circulating in Westminster and the City: that Britain risks becoming an “incubator economy,” a place that builds transformative companies and then watches someone else fund them to scale.
The Terms Are Different Too
It isn't just who invests at the growth stage, the terms shift too.
A standard early-stage term sheet in the UK still runs on 1x non-participating preferred stock: investors get their liquidation preference back first, then take their pro-rata share of whatever's left, but not both. At Series C funding and beyond, that standard starts to bend. Participating preferred stock, where an investor takes their liquidation preference and still shares in the remaining proceeds, has become more common at growth stage - a form of structured equity historically associated with down rounds and bridge financings, now appearing in some ordinary growth-stage term sheets as investors price in more uncertainty about when and how an exit actually arrives.
Valuations have moved with the terms.
Beauhurst's data shows UK growth-stage valuations falling from £68 million in the second half of 2024 to £38 million in the first half of 2025 that is a sharper correction than seed or venture-stage companies saw over the same period, before 2026's AI-driven rebound pulled late-stage numbers back up, and as per HSBC Innovation Banking's 2026 Venture Capital Term Sheet Guide, drawn from 711 completed UK term sheets, nearly two-thirds of Series B and C+ rounds last year were led by investors from outside the UK, representing £5.9 billion of capital.
It's now the clearest evidence yet that the growth equity funds shaping British companies' cap tables increasingly aren't British ones.
What We're Watching
There's an optimistic version of this story and a less comfortable one, and we think both are true at the same time.
The optimistic version: British-founded companies are good enough that the world's largest growth equity funds, sovereign-adjacent industrial capital and strategic corporate money all want in, and Britain no longer has to watch its most promising companies stall out for lack of a cheque.
The less comfortable version is, by the time many of these companies reach an exit, the proportion of them meaningfully owned by British capital may be smaller than most people currently assume, and the pension money that was supposed to change that arithmetic is arriving at roughly a tenth of the pace the 2030 deadline requires.
We don't think that tension resolves cleanly in either direction yet, but what's clear is that “who's investing” has become a more complicated question than “how much,” and it's one worth asking again in twelve months, once this year's Series C funding rounds start reaching the exits that will actually test whose money it was.
Read next: The Top UK VC Firms in 2026 and What They Invest In
Sources: HSBC Innovation Banking & Dealroom, UK Innovation Update H1 2026 and Venture Capital Term Sheet Guide 2026 · Beauhurst, State of UK Investment H1 2025 · UK Private Capital (formerly BVCA) · Association of British Insurers, Mansion House Compact progress update · British Business Bank · Nscale, Wayve, PhysicsX and Isomorphic Labs funding announcements · TechCrunch · CNBC · Sacra.
